Copin M C, Noel C, Hazzan M, Janin A, Pruvot F R, Dessaint J P, Lelievre G, Gosselin B
Department of Pathology, Hôpital Calmette, Centre Hospitalier et Universitaire de Lille, France.
Transpl Immunol. 1995 Sep;3(3):229-39. doi: 10.1016/0966-3274(95)80029-8.
We have retrospectively studied the diagnostic and predictive value of immunohistochemical characterization of adhesion molecules (ICAM-1, CD54, VCAM-1) and HLA-DR antigen in a homogeneous clinical group of 36 patients. Between 1 January 1991 and 31 January 1993, 130 patients received a kidney transplant in our unit. Biopsies of renal allografts were only performed in asymptomatic patients who had graft dysfunction, revealed by an isolated serum creatinine increase. Available frozen samples were included in this study (n = 44). The 35 cases of acute rejection diagnosed by biopsy corresponded to mild acute rejection according to the Banff classification criteria. First, we compared the expression of HLA-DR, ICAM-1 and VCAM-1 to morphological data to determine if the immunohistochemical data improved the histopathological diagnosis when the interstitial infiltrate was mild with slight tubulitis. We also studied the phenotype of infiltrating cells with monoclonal antibodies directed against T helper cells, T cytotoxic-suppressor cells, activated T cells and macrophages. Expression on tubular epithelium and density of each type of cell was graded semiquantitatively. Expression of HLA-DR, ICAM-1 and VCAM-1 was observed on tubular epithelium and endothelium in both acute rejection and other causes of graft dysfunction, limiting its diagnostic value. Activated T cells expressing CD69-AIM (activation inducer molecule) and/or HLA-DR were frequently observed in acute rejection (24/35 (69%) and 25/35 (71%) respectively) but not in other causes of renal dysfunction. We then studied the prognostic usefulness of the immunohistochemical profile in acute rejection. Of 27 patients, 12 had a progressively decreased renal function or returned to dialysis within one year after transplantation while the other 15 had a stable graft function after at least 18 months of follow-up. In the group of bad prognosis (n = 12), corticosteroid-resistant rejection episodes were significantly more frequent (p < 0.01). In this group, nine patients had an overexpression of HLA-DR on tubular epithelium versus one patient in the group of stable graft function (chi 2c = 10.57, p < 0.002). Seven patients included in the group of bad prognosis showed tubular overexpression of both ICAM-1 and VCAM-1 versus one patient in the other group chi 2c = 6.23, p < 0.02). Moreover, patients of the first group had a significantly higher number of interstitial macrophages as compared with those who had stable graft function (chi 2c = 4.87, p < 0.01). Thus, our data show that the immunohistochemical profile studied is of little value in the diagnosis of renal allograft rejection. However, an intense tubular expression of HLA-DR and/or both ICAM-1 and VCAM-1, and a high number of interstitial macrophages are significantly related to unfavorable graft outcome.
我们回顾性研究了粘附分子(ICAM-1、CD54、VCAM-1)免疫组化特征及HLA-DR抗原在36例同质性临床患者中的诊断和预测价值。1991年1月1日至1993年1月31日期间,我院有130例患者接受了肾移植。仅对移植肾功能异常(表现为单纯血清肌酐升高)的无症状患者进行了同种异体肾活检。本研究纳入了可用的冷冻样本(n = 44)。根据Banff分类标准,经活检诊断的35例急性排斥反应均为轻度急性排斥。首先,我们将HLA-DR、ICAM-1和VCAM-1的表达与形态学数据进行比较,以确定当间质浸润较轻且伴有轻微肾小管炎时,免疫组化数据是否能改善组织病理学诊断。我们还使用针对辅助性T细胞、细胞毒性抑制性T细胞、活化T细胞和巨噬细胞的单克隆抗体研究了浸润细胞的表型。对肾小管上皮细胞上的表达及每种细胞类型的密度进行半定量分级。在急性排斥反应和其他移植功能障碍原因中,均观察到HLA-DR、ICAM-1和VCAM-1在肾小管上皮和内皮上的表达,这限制了其诊断价值。在急性排斥反应中,经常观察到表达CD69-AIM(活化诱导分子)和/或HLA-DR的活化T细胞(分别为24/35(69%)和25/35(71%)),而在其他肾功能障碍原因中则未观察到。然后,我们研究了免疫组化特征在急性排斥反应中的预后价值。27例患者中,12例在移植后一年内肾功能逐渐下降或恢复透析,而另外15例在至少18个月的随访后移植功能稳定。在预后不良组(n = 12)中,对皮质类固醇耐药的排斥反应发生率显著更高(p < 0.01)。该组中,9例患者肾小管上皮HLA-DR过表达,而移植功能稳定组中只有1例(卡方检验c = 10.57,p < 0.002)。预后不良组中有7例患者肾小管ICAM-1和VCAM-1均过表达,而另一组中只有1例(卡方检验c = 6.23,p < 0.02)。此外,与移植功能稳定的患者相比,第一组患者间质巨噬细胞数量显著更多(卡方检验c = 4.87,p < 0.01)。因此,我们的数据表明,所研究的免疫组化特征在同种异体肾移植排斥反应的诊断中价值不大。然而,HLA-DR和/或ICAM-1及VCAM-1在肾小管上的强烈表达,以及大量间质巨噬细胞与移植不良结局显著相关。